Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 17/20 | 1.00 |
| ▸ | MERTK | Q12866 | 3/20 | 0.86 |
| ▸ | MET | P08581 | 11/20 | 0.86 |
| ▸ | AURKA | O14965 | 1/20 | 0.86 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.86 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.86 |
| ▸ | ABL1 | P00519 | 1/20 | 0.86 |
| ▸ | EGFR | P00533 | 1/20 | 0.86 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.86 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.86 |
| ▸ | LCK | P06239 | 1/20 | 0.86 |
| ▸ | PGR | P06401 | 1/20 | 0.86 |
| ▸ | LYN | P07948 | 1/20 | 0.86 |
| ▸ | RET | P07949 | 1/20 | 0.86 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.86 |
| ▸ | HCK | P08631 | 1/20 | 0.86 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.86 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.86 |
| ▸ | KIT | P10721 | 1/20 | 0.86 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21200618 | 1.00 | AXL (1.00) | AXLMERTKMETAURKARIPK2 | |
| SCHEMBL30152738 | 0.97 | AXL (1.00) | AXLMERTKMETAURKARIPK2 | |
| SCHEMBL21200707 | 0.97 | AXL (1.00) | AXLMERTKMETAURKARIPK2 | |
| SCHEMBL21200616 | 0.93 | AXL (0.86) | AXLMERTKMETAURKARIPK2 | |
| SCHEMBL30152488 | 0.93 | AXL (0.86) | AXLMERTKMETAURKARIPK2 | |
| SCHEMBL21200592 | 0.93 | AXL (1.00) | AXLMERTKMETAURKARIPK2 | |
| SCHEMBL29558456 | 0.93 | AXL (1.00) | AXLMERTKMETAURKARIPK2 | |
| Cabozantinib SCHEMBL29351408 | 0.93 | AXL (1.00) | AXLMERTKMETAURKARIPK2 | |
| Cabozantinib SCHEMBL29728791 | 0.93 | AXL (1.00) | AXLMERTKMETAURKARIPK2 | |
| Cabozantinib SCHEMBL360795 | 0.93 | AXL (1.00) | AXLMERTKMETAURKARIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4647127-A2 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-02-08 | — | — | US | claimed |
| EP-4647127-A2 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4631505-A2 | CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITOR | Exelixis, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-3743070-B1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-3894012-B1 | CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITOR | EXELIXIS INC (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4240333-A1 | PHARMACEUTICAL COMPOSITIONS OF A KINASE INHIBITOR | Exelixis, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4188376-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | Exelixis, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022098828-A1 | PHARMACEUTICAL COMPOSITIONS OF A KINASE INHIBITOR | EXELIXIS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, MAP3K1 | AXL 269/4885MERTK 31/4885MET 154/4885 |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | AXL 269/4885MERTK 31/4885MET 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.